Babyfolio
Software Engineer, AI Infrastructure Investor
IQE's bottleneck position in AI optics is already priced in, so the easy money is gone until its revenue and profits grow. Per @jpinsights, IQE grows the indium phosphide epiwafers high-speed lasers are built from, and validation came through MACOM's GBP45m investment, Tower's multi-year supply deal and a GBP81m raise. But the stock has rerated hard, and it is unclear whether any of this has reached IQE's own numbers. x.com
IQE is hard to call undervalued because its price already embeds a mature-margin scenario two-plus years out. At a 15% margin and 20% yearly growth, FY28 EBITDA is about GBP25 million, worth about GBP500 million at a generous 20x, versus a GBP520 million market cap at 40p. IQE earns about 3% adjusted EBITDA margins versus LandMark's high-margin epi, MACOM's convertible and warrants carry about 76 million shares of overhang, and InP supply constraints threaten its H2-weighted guide. x.com x.com … Show more
IQE's outsourced epitaxy business is structurally disadvantaged because demanding optics customers want the whole chain under their own control. Big integrated players such as Lumentum and Applied Optoelectronics run their own reactors and want to control manufacturing conditions throughout. Shipping wafers to an outside fab for epi growth and back falls short of that ideal, so regardless of IQE's execution the business model is unappealing, even as @crux_capital_ turns more positive. x.com
IQE is priced for skepticism it no longer deserves, while Sivers Semiconductors is priced for perfection it has not delivered, though both sit in the same AI optical chain. Sivers trades at about 85x sales with negative EBITDA, and Q1 revenue missed. IQE trades near 4-5x sales, is EBITDA positive, guides 20%+ growth to at least £117M in 2026, has cleared bank debt with MACOM's backing, and trades far below peer LandMark at about 70x forward. Sivers is worth revisiting only if its price resets. … Show more
IQE is held above its fundamental fair value by optimistic expectations, and its takeover thesis is effectively dead. With MACOM as anchor investor holding board seats and exclusive long-term supply deals, a bidding war is practically ruled out. The 19.8p placing, a 58% discount, takes dilution since early 2025 to about 42%, and the £81 million mostly repays debt, so capex needs another raise within 18-24 months. If momentum fades the stock will fall; if it strengthens, it can keep rising. x.com
IQE's 43% first-half revenue growth overstates the recovery, because the group is still slightly smaller than two years ago. Photonics is a genuine breakout at £38.5m, 44% above H1 2024, but wireless at £26.0m remains a third below that level and is still recovering. A £4.0m working-capital outflow absorbed the margin gain, 61% of May's £81m raise went to lenders, and depreciation runs about nine times capex. Converted InP lines delivering H2 volume without more capex would prove efficiency. … Show more
IQE still has plenty of upside as Tower Semiconductor's indium phosphide epitaxial wafer supplier for the NPO-to-CPO buildout. Tower said its multi-year epi wafer agreement with IQE leaves it extremely well positioned against the InP bottleneck. Tower's first NPO deployments come in 2027, with $1.3B of contract value for that year and higher numbers expected after, and it plans to quadruple Japanese silicon photonics capacity, with full readiness in Q4 2027. x.com x.com x.com
AI bandwidth demand still favors Coherent and Lumentum, but tight customer financing can delay orders and lasting valuations need durable profits. A model provider losing share need not reduce total bandwidth use. Coherent could beat and raise guidance; Lumentum may only meet estimates this quarter, improving next quarter. If margins partly reflect scarce indium phosphide, added supply will test whether upgrades, volume and cost gains sustain earnings. These earnings calls remain forecasts. … Show more
AXT's upside looks capped because its valuation already prices in a near-flawless indium phosphide capacity ramp. Doubling its ~25k wafers a year by end-2026 and again by end-2027 gives ~100k, about 4x, likely with some multiple compression. Even with ~58% growth to 2028, 60% gross-profit growth after and a 20x EV/GP multiple, EV reaches only ~$6.9B in five years versus $6.1B now. Only surprise capacity beyond 2027 changes the math; Soitec, at 19x EV/GP, is the better play. x.com x.com
IQE's new multi-year indium phosphide epiwafer supply deal with Tower Semiconductor puts a 5x-10x move from March 2026 levels in the works, and IQE is the pick over Tower itself. Per Wall St Engine, the wafers support Tower's silicon photonics platforms for AI data center optics, including 200G/lane pluggable transceivers, 400G/lane modulator prototypes and optical circuit switches. The two also settled their IP dispute, with Tower granting IQE a worldwide royalty-free license. x.com x.com
AXT remains a vital InP substrate bottleneck, and keeping some exposure makes sense because a ton of AI capex flows directly to it, though much is priced in. Transceivers moving from 800G to 1.6T and 3.2T need lasers built on InP substrates, which AXT and Sumitomo supply; demand exceeds supply even as AXT doubles capacity by end-2026. Management sees CPO inflecting late 2027 and beyond. Earnings should improve as backlog converts, though another parabolic move looks unlikely. x.com x.com
